Home > Press Releases > Protein Degraders (PROTACs & Molecular Glues) Market

Protein Degraders (PROTACs & Molecular Glues) Market Likely to Surpass ~USD 4 Billion by 2035

Report Code: HC-72467  |  Published in: Oct 2025, By MarketGenics  |  Number of pages: 317
Get PDF
Buy

Exploring novel growth opportunities on, “Protein Degraders (PROTACs & Molecular Glues) Market Size, Share & Trends Analysis Report by Technology Type (PROTACs (Proteolysis Targeting Chimeras), Molecular Glues, Hybrid Degraders, Homo-PROTACs, CLIPTAC (CLIck-formed Proteolysis TArgeting Chimera), Others), Target Protein Class, E3 Ligase Type, Molecule Type, Route of Administration, Therapeutic Application, Drug Development Stage, Linker Chemistry, Molecular Weight, Degradation Mechanism, Distribution Channel, End-users, and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035” A complete report exploring emerging market pathways in the Protein Degraders (PROTACs & Molecular Glues) market illuminates revenue acceleration levers highlighting how scalable product line extensions, targeted new-market entries, and strategic partnerships are poised to drive top-line growth, expand market share.

Global Protein Degraders (PROTACs & Molecular Glues) Market Forecast 2035:

According to the report, the global protein degraders (protacs & molecular glues) market is likely to grow from USD 0.5 Billion in 2025 to USD 3.7 Billion in 2035 at a highest CAGR of ~22% during the time period. The growth of the protein degraders (protacs and molecular glues) market is fueled by the deployment of improved technologies, such as AI-based drug discoveries platforms, machine learning-based target prediction, high-throughput screening, computational modeling, and data-driven molecular optimization tools to improve therapeutic efficacy, speed up drug development, and have precision-targeted degradation of the disease-associated proteins of both pharmaceutical companies and research organizations.

The market of protein degraders (protacs and molecular glues) is reshaped by scientific and technological advancements in the fields of AI-based molecular modeling, cryo-EM structural visualization, and machine learning-based design of degraders to discover and accelerate precision medicine. These innovations are facilitating quicker recognition of ligase substrate couples, enhancing the selectivity of degraders and expanding the pharmacokinetic qualities to achieve better therapeutic results. For instance, in August 2025, Proxygen has developed its AI-driven, molecular glue discovery platform, which integrates high-throughput screening with structural modeling to discover new ligase-substrate interactions. The company plans to expand its glue degrader pipeline in 2025 by entering into strategic partnerships to speed up the development of drugs to treat oncology and neurodegenerative diseases.

Moreover, biotech innovators are incorporating digital simulation such as Arvinas, Magnet Biomedicine, Proxygen along with automated screening systems and cloud-based data analytics to simplify degrader development and clinical translation. Such combination of computational intelligence and experimental validation on the high-throughput scale is forming an efficient, scalable, less-cost drug development process. The creation of synergies between innovative technologies, favorable regulatory frameworks, and strategic partnerships are making the Protein Degraders (PROTACs and Molecular Glues) market placeable towards sustainable growth and expanded therapeutic applications across the globe.

“Key Driver, Restraint, and Growth Opportunity Shaping the Global Protein Degraders (PROTACs & Molecular Glues) Market”

The market of protein degraders (protacs and molecular glues) is becoming more and more concentrated on the necessity to use personalized and precision therapeutics especially in oncology, neurodegenerative disorders, and rare diseases. The development of biomarker, genomics, and proteomics enable the degraders to be designed to fit the disease profile of a certain individual, which results in greater efficacy and less off-target effects. For instance, in July 2024, MindRank, an AI-empowered clinical-stage drug discovery firm, began an IND-enabling study of its AI-designed molecular glue, MRANK-103, against the MYC signaling pathway. This technique is expected to control eukaryotic translation and transcription factors to promote highly individualized treatment regimens. This level of high-tech, accuracy-focused solutions will render Protein Degraders more convenient, efficient, and applicable to clinical use, leading to improved patient outcomes and enhanced use in a wider range of treatment fields.

The protein degraders (protacs and molecular glues) industry is hampered by limited trust and awareness. Consumers and health professionals do not have information on the benefits of PROTACs and molecular glues such as the capability of targeting the hitherto non-druggable proteins and offering targeted treatment choices, which leads to low adoption. A lack of confidence in these therapies also impedes trust. Any misunderstanding of clinical outcome, off-target potential effects or mismatched messaging can further discourage usage. Such struggles are more pronounced in localities that have low levels of scientific literacy, lack access to educational materials and low levels of patient engagement programs. Minimal awareness and consultations delay the penetration and adoption of the market.

Protein degraders (protacs and molecular glues) are recognized by regulatory bodies, healthcare institutions, and medical centers worldwide as important factors in facilitating precision and personalized therapeutics to patients with cancer, neurodegenerative diseases, and rare diseases. Research grants, expedited approval pathways, and public-private initiatives on innovative targeted therapies are some of the supportive measures developed by many countries so that they can promote adoption. Such programs reduce the financial and operational cost to biotech companies and healthcare providers making custom degrader-based therapies. The various molecular profiles could be customized to their unique therapies according to this framework, enhancing selectivity, maximizing response to treatment and reducing the adverse effects that may occur. These measures will support wider implementation, improved patient care, and positive promotion of precision and personalized medicine on the international healthcare systems.

Impact of Tariff Rates on the global Protein Degraders (PROTACs & Molecular Glues) Market

  • Tariff rates are one of the key determinants of the protein degraders (protacs and molecular glues) market across the globe since it affects the price, availability, and supply chain of raw materials, research reagents, and completed therapeutics. Specialty chemicals, biologics or laboratory equipment attract high import tariffs, which raise production costs in biotech companies, which then translate into higher end product prices, which can restrict market penetration in the market, particularly in the emerging economies.
  • On the other hand, lower or equal tariffs will help to streamline international trade, which will help to distribute PROTACs and molecular glues within international markets in a short time. Strategic alliances and licensing agreements between multinational pharma and biotech companies can also be influenced by tariff changes, since the costs might not be predictable, and this can lead to projects not being viable.
  • In addition, nations with reduced tariff protection receive investments in local manufacturing and research, which bring about innovation and ensure that desired protein degradation drugs are initially brought into the markets of the world.

Regional Analysis of Global Protein Degraders (PROTACs & Molecular Glues) Market

  • The North American market of protein degraders (protacs, molecular glues) occupies the greatest share due to a strong digital health setting, advanced healthcare system, and consumer awareness of preventive well-being. Companies such as U.S. National Institutes of Health (NIH) and Health Canada are involved in promoting research and development of protein degradation therapies by providing grants and funding innovative drug discovery solutions. Moreover, innovative development of AI-based drug discovery systems, target engagement via proteomics, and tailored therapeutic development, government-funded health initiatives, and a mature commercial pharmaceutical industry, are all reinforcers of the North American primacy in the global protein degraders (protacs and molecular glues) market.
  • Asia-Pacific protein degraders (protacs and molecular glues) market is projected to experience the highest growth rate in the world due to increasing population, growing urbanization and rising healthcare awareness in China, India and Japan amongst others. Cancer, neurodegenerative, and other forms of chronic diseases are becoming increasingly prevalent, and more and more people will be accessing high-quality healthcare infrastructure, increasing demand on specific forms of protein-degradation therapies. Ongoing innovations in proteomics, structural biology, and AI-oriented drug discoveries technologies, combined with the integration of digital health and biomarker profiling, are tipping the region towards the creation and delivery of personalized and precision therapeutics. Favored governmental regulations, increased biotech investments, and additional pharmaceutical research facilities also play a role in making Asia-Pacific the most rapidly growing market in the world Protein Degraders.

Prominent players operating in the global protein degraders (protacs & molecular glues) market are AbbVie Inc., Amgen Inc., Arvinas, Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb (Celgene), C4 Therapeutics, Inc., Captor Therapeutics S.A., Dialectic Therapeutics, Inc., Eli Lilly and Company, Gilead Sciences, Inc., GSK plc (GlaxoSmithKline), Janssen Pharmaceuticals (Johnson & Johnson), Kymera Therapeutics, Inc., Merck & Co., Inc., Novartis AG, Nurix Therapeutics, Inc., Pfizer Inc., Roche Holding AG (Genentech), Sanofi S.A., Takeda Pharmaceutical Company Limited, Other Key Players.

The global Protein Degraders (PROTACs & Molecular Glues) market has been segmented as follows:

Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, By Technology Type

  • PROTACs (Proteolysis Targeting Chimeras)
  • Molecular Glues
  • Hybrid Degraders
  • Homo-PROTACs
  • CLIPTAC (CLIck-formed Proteolysis TArgeting Chimera)
  • Others

Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, By Target Protein Class

  • Kinases
  • Transcription Factors
  • Nuclear Receptors
  • Epigenetic Proteins
  • Scaffolding Proteins
  • Membrane Proteins
  • BTK (Bruton's Tyrosine Kinase)
  • IRAK4 (Interleukin-1 Receptor-Associated Kinase 4)
  • Others

Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, By E3 Ligase Type

  • Cereblon (CRBN)-based
  • Von Hippel-Lindau (VHL)-based
  • MDM2 (Mouse Double Minute 2)-based
  • IAP (Inhibitor of Apoptosis Protein)-based
  • DCAF15-based
  • DCAF16-based
  • Others

Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, By Molecule Type

  • Small Molecule Degraders
  • Peptide-based Degraders
  • Antibody-conjugated Degraders
  • Nucleic Acid-based Degraders

Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, By Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Intramuscular
  • Others

Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, By Therapeutic Application

  • Oncology (Cancer)
  • Hematological Malignancies
    • Solid Tumors
    • Prostate Cancer
    • Breast Cancer
    • Lung Cancer
    • Others
  • Neurodegenerative Diseases
    • Alzheimer's Disease
    • Parkinson's Disease
    • Others
  • Immunological Disorders
  • Cardiovascular Diseases
  • Metabolic Disorders
  • Infectious Diseases
  • Others

Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, By Drug Development Stage

  • Discovery Stage
  • Preclinical Stage
  • Phase I Clinical Trials
  • Phase II Clinical Trials
  • Phase III Clinical Trials
  • Approved/Commercialized

Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, By Linker Chemistry

  • Alkyl Chain Linkers
  • PEG (Polyethylene Glycol) Linkers
  • Rigid Linkers
  • Cleavable Linkers
  • Non-cleavable Linkers

Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, By Molecular Weight

  • Low Molecular Weight (<500 Da)
  • Medium Molecular Weight (500-1000 Da)
  • High Molecular Weight (>1000 Da)

Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, By Degradation Mechanism

  • Ubiquitin-Proteasome System (UPS)
  • Lysosomal Degradation
  • Autophagy-based Degradation

Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Clinics

Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, By End Users

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutions
  • Contract Research Organizations (CROs)
  • Hospitals & Cancer Centers
  • Diagnostic Laboratories
  • Clinical Trial Sites
  • Others

Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, by Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Protein Degraders (PROTACs & Molecular Glues) Market Outlook
      • 2.1.1. Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2025-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
      • 3.1.1. Industry Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
    • 3.4. Trade Analysis
      • 3.4.1. Import & Export Analysis, 2025
      • 3.4.2. Top Importing Countries
      • 3.4.3. Top Exporting Countries
    • 3.5. Trump Tariff Impact Analysis
      • 3.5.1. Manufacturer
        • 3.5.1.1. Based on the component & Raw material
      • 3.5.2. Supply Chain
      • 3.5.3. End Consumer
    • 3.6. Raw Material Analysis
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Expansion of the druggable proteome, PROTACs & molecular glues can target undruggable proteins, opening new therapeutic opportunities.
        • 4.1.1.2. Rising R&D investment, strategic partnerships and biopharma collaborations accelerating discovery and clinical pipelines.
        • 4.1.1.3. Growing unmet need from oncology and neurodegenerative diseases driving demand for novel protein-degrading therapies.
      • 4.1.2. Restraints
        • 4.1.2.1. High development cost, complex optimization and limited clinical/safety data slowing commercialization.
        • 4.1.2.2. IP, manufacturing challenges and regulatory uncertainty around novel degrader modalities.
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Value Chain Analysis
      • 4.4.1. Research & Discovery
      • 4.4.2. Preclinical Development & Clinical Development
      • 4.4.3. Regulatory Approvals
      • 4.4.4. Distribution & Commercialization
    • 4.5. Cost Structure Analysis
      • 4.5.1. Parameter’s Share for Cost Associated
      • 4.5.2. COGP vs COGS
      • 4.5.3. Profit Margin Analysis
    • 4.6. Pricing Analysis
      • 4.6.1. Regional Pricing Analysis
      • 4.6.2. Segmental Pricing Trends
      • 4.6.3. Factors Influencing Pricing
    • 4.7. Porter’s Five Forces Analysis
    • 4.8. PESTEL Analysis
    • 4.9. Global Protein Degraders (PROTACs & Molecular Glues) Market Demand
      • 4.9.1. Historical Market Size – Value (US$ Bn), 2020-2024
      • 4.9.2. Current and Future Market Size - Value (US$ Bn), 2025–2035
        • 4.9.2.1. Y-o-Y Growth Trends
        • 4.9.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, by Technology Type
    • 6.1. Key Segment Analysis
    • 6.2. Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), Analysis, and Forecasts, by Technology Type, 2021-2035
      • 6.2.1. PROTACs (Proteolysis Targeting Chimeras)
      • 6.2.2. Molecular Glues
      • 6.2.3. Hybrid Degraders
      • 6.2.4. Homo-PROTACs
      • 6.2.5. CLIPTAC (CLIck-formed Proteolysis TArgeting Chimera)
      • 6.2.6. Others
  • 7. Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, by Target Protein Class
    • 7.1. Key Segment Analysis
    • 7.2. Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), Analysis, and Forecasts, by Target Protein Class, 2021-2035
      • 7.2.1. Kinases
      • 7.2.2. Transcription Factors
      • 7.2.3. Nuclear Receptors
      • 7.2.4. Epigenetic Proteins
      • 7.2.5. Scaffolding Proteins
      • 7.2.6. Membrane Proteins
      • 7.2.7. BTK (Bruton's Tyrosine Kinase)
      • 7.2.8. IRAK4 (Interleukin-1 Receptor-Associated Kinase 4)
      • 7.2.9. Others
  • 8. Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, by E3 Ligase Type
    • 8.1. Key Segment Analysis
    • 8.2. Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), Analysis, and Forecasts, by E3 Ligase Type, 2021-2035
      • 8.2.1. Cereblon (CRBN)-based
      • 8.2.2. Von Hippel-Lindau (VHL)-based
      • 8.2.3. MDM2 (Mouse Double Minute 2)-based
      • 8.2.4. IAP (Inhibitor of Apoptosis Protein)-based
      • 8.2.5. DCAF15-based
      • 8.2.6. DCAF16-based
      • 8.2.7. Others
  • 9. Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, by Molecule Type
    • 9.1. Key Segment Analysis
    • 9.2. Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), Analysis, and Forecasts, by Molecule Type, 2021-2035
      • 9.2.1. Small Molecule Degraders
      • 9.2.2. Peptide-based Degraders
      • 9.2.3. Antibody-conjugated Degraders
      • 9.2.4. Nucleic Acid-based Degraders
  • 10. Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, by Route of Administration
    • 10.1. Key Segment Analysis
    • 10.2. Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), Analysis, and Forecasts, by Route of Administration, 2021-2035
      • 10.2.1. Oral
      • 10.2.2. Intravenous
      • 10.2.3. Subcutaneous
      • 10.2.4. Intramuscular
      • 10.2.5. Others
  • 11. Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, by Therapeutic Application
    • 11.1. Key Segment Analysis
    • 11.2. Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapeutic Application, 2021-2035
      • 11.2.1. Oncology (Cancer)
        • 11.2.1.1. Hematological Malignancies
        • 11.2.1.2. Solid Tumors
        • 11.2.1.3. Prostate Cancer
        • 11.2.1.4. Breast Cancer
        • 11.2.1.5. Lung Cancer
        • 11.2.1.6. Others
      • 11.2.2. Neurodegenerative Diseases
        • 11.2.2.1. Alzheimer's Disease
        • 11.2.2.2. Parkinson's Disease
        • 11.2.2.3. Others
      • 11.2.3. Immunological Disorders
      • 11.2.4. Cardiovascular Diseases
      • 11.2.5. Metabolic Disorders
      • 11.2.6. Infectious Diseases
      • 11.2.7. Others
  • 12. Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, by Drug Development Stage
    • 12.1. Key Segment Analysis
    • 12.2. Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), Analysis, and Forecasts, by Drug Development Stage, 2021-2035
      • 12.2.1. Discovery Stage
      • 12.2.2. Preclinical Stage
      • 12.2.3. Phase I Clinical Trials
      • 12.2.4. Phase II Clinical Trials
      • 12.2.5. Phase III Clinical Trials
      • 12.2.6. Approved/Commercialized
  • 13. Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, by Linker Chemistry
    • 13.1. Key Segment Analysis
    • 13.2. Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), Analysis, and Forecasts, by Linker Chemistry, 2021-2035
      • 13.2.1. Alkyl Chain Linkers
      • 13.2.2. PEG (Polyethylene Glycol) Linkers
      • 13.2.3. Rigid Linkers
      • 13.2.4. Cleavable Linkers
      • 13.2.5. Non-cleavable Linkers
  • 14. Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, by Molecular Weight
    • 14.1. Key Segment Analysis
    • 14.2. Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), Analysis, and Forecasts, by Molecular Weight, 2021-2035
      • 14.2.1. Low Molecular Weight (<500 Da)
      • 14.2.2. Medium Molecular Weight (500-1000 Da)
      • 14.2.3. High Molecular Weight (>1000 Da)
  • 15. Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, by Degradation Mechanism
    • 15.1. Key Segment Analysis
    • 15.2. Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), Analysis, and Forecasts, by Degradation Mechanism, 2021-2035
      • 15.2.1. Ubiquitin-Proteasome System (UPS)
      • 15.2.2. Lysosomal Degradation
      • 15.2.3. Autophagy-based Degradation
  • 16. Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, by Distribution Channel
    • 16.1. Key Segment Analysis
    • 16.2. Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), Analysis, and Forecasts, by Distribution Channel, 2021-2035
      • 16.2.1. Hospital Pharmacies
      • 16.2.2. Retail Pharmacies
      • 16.2.3. Online Pharmacies
      • 16.2.4. Specialty Clinics
  • 17. Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis, by End-users
    • 17.1. Key Segment Analysis
    • 17.2. Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), Analysis, and Forecasts, by End-users, 2021-2035
      • 17.2.1. Pharmaceutical & Biotechnology Companies
      • 17.2.2. Academic & Research Institutions
      • 17.2.3. Contract Research Organizations (CROs)
      • 17.2.4. Hospitals & Cancer Centers
      • 17.2.5. Diagnostic Laboratories
      • 17.2.6. Clinical Trial Sites
      • 17.2.7. Others
  • 18. Global Protein Degraders (PROTACs & Molecular Glues) Market Analysis and Forecasts, by Region
    • 18.1. Key Findings
    • 18.2. Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
      • 18.2.1. North America
      • 18.2.2. Europe
      • 18.2.3. Asia Pacific
      • 18.2.4. Middle East
      • 18.2.5. Africa
      • 18.2.6. South America
  • 19. North America Protein Degraders (PROTACs & Molecular Glues) Market Analysis
    • 19.1. Key Segment Analysis
    • 19.2. Regional Snapshot
    • 19.3. North America Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 19.3.1. Technology Type
      • 19.3.2. Target Protein Class
      • 19.3.3. E3 Ligase Type
      • 19.3.4. Molecule Type
      • 19.3.5. Route of Administration
      • 19.3.6. Therapeutic Application
      • 19.3.7. Drug Development Stage
      • 19.3.8. Linker Chemistry
      • 19.3.9. Molecular Weight
      • 19.3.10. Degradation Mechanism
      • 19.3.11. Distribution Channel
      • 19.3.12. End-users
      • 19.3.13. Country
        • 19.3.13.1. USA
        • 19.3.13.2. Canada
        • 19.3.13.3. Mexico
    • 19.4. USA Protein Degraders (PROTACs & Molecular Glues) Market
      • 19.4.1. Country Segmental Analysis
      • 19.4.2. Technology Type
      • 19.4.3. Target Protein Class
      • 19.4.4. E3 Ligase Type
      • 19.4.5. Molecule Type
      • 19.4.6. Route of Administration
      • 19.4.7. Therapeutic Application
      • 19.4.8. Drug Development Stage
      • 19.4.9. Linker Chemistry
      • 19.4.10. Molecular Weight
      • 19.4.11. Degradation Mechanism
      • 19.4.12. Distribution Channel
      • 19.4.13. End-users
    • 19.5. Canada Protein Degraders (PROTACs & Molecular Glues) Market
      • 19.5.1. Country Segmental Analysis
      • 19.5.2. Technology Type
      • 19.5.3. Target Protein Class
      • 19.5.4. E3 Ligase Type
      • 19.5.5. Molecule Type
      • 19.5.6. Route of Administration
      • 19.5.7. Therapeutic Application
      • 19.5.8. Drug Development Stage
      • 19.5.9. Linker Chemistry
      • 19.5.10. Molecular Weight
      • 19.5.11. Degradation Mechanism
      • 19.5.12. Distribution Channel
      • 19.5.13. End-users
    • 19.6. Mexico Protein Degraders (PROTACs & Molecular Glues) Market
      • 19.6.1. Country Segmental Analysis
      • 19.6.2. Technology Type
      • 19.6.3. Target Protein Class
      • 19.6.4. E3 Ligase Type
      • 19.6.5. Molecule Type
      • 19.6.6. Route of Administration
      • 19.6.7. Therapeutic Application
      • 19.6.8. Drug Development Stage
      • 19.6.9. Linker Chemistry
      • 19.6.10. Molecular Weight
      • 19.6.11. Degradation Mechanism
      • 19.6.12. Distribution Channel
      • 19.6.13. End-users
  • 20. Europe Protein Degraders (PROTACs & Molecular Glues) Market Analysis
    • 20.1. Key Segment Analysis
    • 20.2. Regional Snapshot
    • 20.3. Europe Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 20.3.1. Technology Type
      • 20.3.2. Target Protein Class
      • 20.3.3. E3 Ligase Type
      • 20.3.4. Molecule Type
      • 20.3.5. Route of Administration
      • 20.3.6. Therapeutic Application
      • 20.3.7. Drug Development Stage
      • 20.3.8. Linker Chemistry
      • 20.3.9. Molecular Weight
      • 20.3.10. Degradation Mechanism
      • 20.3.11. Distribution Channel
      • 20.3.12. End-users
      • 20.3.13. Country
        • 20.3.13.1. Germany
        • 20.3.13.2. United Kingdom
        • 20.3.13.3. France
        • 20.3.13.4. Italy
        • 20.3.13.5. Spain
        • 20.3.13.6. Netherlands
        • 20.3.13.7. Nordic Countries
        • 20.3.13.8. Poland
        • 20.3.13.9. Russia & CIS
        • 20.3.13.10. Rest of Europe
    • 20.4. Germany Protein Degraders (PROTACs & Molecular Glues) Market
      • 20.4.1. Country Segmental Analysis
      • 20.4.2. Technology Type
      • 20.4.3. Target Protein Class
      • 20.4.4. E3 Ligase Type
      • 20.4.5. Molecule Type
      • 20.4.6. Route of Administration
      • 20.4.7. Therapeutic Application
      • 20.4.8. Drug Development Stage
      • 20.4.9. Linker Chemistry
      • 20.4.10. Molecular Weight
      • 20.4.11. Degradation Mechanism
      • 20.4.12. Distribution Channel
      • 20.4.13. End-users
    • 20.5. United Kingdom Protein Degraders (PROTACs & Molecular Glues) Market
      • 20.5.1. Country Segmental Analysis
      • 20.5.2. Technology Type
      • 20.5.3. Target Protein Class
      • 20.5.4. E3 Ligase Type
      • 20.5.5. Molecule Type
      • 20.5.6. Route of Administration
      • 20.5.7. Therapeutic Application
      • 20.5.8. Drug Development Stage
      • 20.5.9. Linker Chemistry
      • 20.5.10. Molecular Weight
      • 20.5.11. Degradation Mechanism
      • 20.5.12. Distribution Channel
      • 20.5.13. End-users
    • 20.6. France Protein Degraders (PROTACs & Molecular Glues) Market
      • 20.6.1. Country Segmental Analysis
      • 20.6.2. Technology Type
      • 20.6.3. Target Protein Class
      • 20.6.4. E3 Ligase Type
      • 20.6.5. Molecule Type
      • 20.6.6. Route of Administration
      • 20.6.7. Therapeutic Application
      • 20.6.8. Drug Development Stage
      • 20.6.9. Linker Chemistry
      • 20.6.10. Molecular Weight
      • 20.6.11. Degradation Mechanism
      • 20.6.12. Distribution Channel
      • 20.6.13. End-users
    • 20.7. Italy Protein Degraders (PROTACs & Molecular Glues) Market
      • 20.7.1. Country Segmental Analysis
      • 20.7.2. Technology Type
      • 20.7.3. Target Protein Class
      • 20.7.4. E3 Ligase Type
      • 20.7.5. Molecule Type
      • 20.7.6. Route of Administration
      • 20.7.7. Therapeutic Application
      • 20.7.8. Drug Development Stage
      • 20.7.9. Linker Chemistry
      • 20.7.10. Molecular Weight
      • 20.7.11. Degradation Mechanism
      • 20.7.12. Distribution Channel
      • 20.7.13. End-users
    • 20.8. Spain Protein Degraders (PROTACs & Molecular Glues) Market
      • 20.8.1. Country Segmental Analysis
      • 20.8.2. Technology Type
      • 20.8.3. Target Protein Class
      • 20.8.4. E3 Ligase Type
      • 20.8.5. Molecule Type
      • 20.8.6. Route of Administration
      • 20.8.7. Therapeutic Application
      • 20.8.8. Drug Development Stage
      • 20.8.9. Linker Chemistry
      • 20.8.10. Molecular Weight
      • 20.8.11. Degradation Mechanism
      • 20.8.12. Distribution Channel
      • 20.8.13. End-users
    • 20.9. Netherlands Protein Degraders (PROTACs & Molecular Glues) Market
      • 20.9.1. Country Segmental Analysis
      • 20.9.2. Technology Type
      • 20.9.3. Target Protein Class
      • 20.9.4. E3 Ligase Type
      • 20.9.5. Molecule Type
      • 20.9.6. Route of Administration
      • 20.9.7. Therapeutic Application
      • 20.9.8. Drug Development Stage
      • 20.9.9. Linker Chemistry
      • 20.9.10. Molecular Weight
      • 20.9.11. Degradation Mechanism
      • 20.9.12. Distribution Channel
      • 20.9.13. End-users
    • 20.10. Nordic Countries Protein Degraders (PROTACs & Molecular Glues) Market
      • 20.10.1. Country Segmental Analysis
      • 20.10.2. Technology Type
      • 20.10.3. Target Protein Class
      • 20.10.4. E3 Ligase Type
      • 20.10.5. Molecule Type
      • 20.10.6. Route of Administration
      • 20.10.7. Therapeutic Application
      • 20.10.8. Drug Development Stage
      • 20.10.9. Linker Chemistry
      • 20.10.10. Molecular Weight
      • 20.10.11. Degradation Mechanism
      • 20.10.12. Distribution Channel
      • 20.10.13. End-users
    • 20.11. Poland Protein Degraders (PROTACs & Molecular Glues) Market
      • 20.11.1. Country Segmental Analysis
      • 20.11.2. Technology Type
      • 20.11.3. Target Protein Class
      • 20.11.4. E3 Ligase Type
      • 20.11.5. Molecule Type
      • 20.11.6. Route of Administration
      • 20.11.7. Therapeutic Application
      • 20.11.8. Drug Development Stage
      • 20.11.9. Linker Chemistry
      • 20.11.10. Molecular Weight
      • 20.11.11. Degradation Mechanism
      • 20.11.12. Distribution Channel
      • 20.11.13. End-users
    • 20.12. Russia & CIS Protein Degraders (PROTACs & Molecular Glues) Market
      • 20.12.1. Country Segmental Analysis
      • 20.12.2. Technology Type
      • 20.12.3. Target Protein Class
      • 20.12.4. E3 Ligase Type
      • 20.12.5. Molecule Type
      • 20.12.6. Route of Administration
      • 20.12.7. Therapeutic Application
      • 20.12.8. Drug Development Stage
      • 20.12.9. Linker Chemistry
      • 20.12.10. Molecular Weight
      • 20.12.11. Degradation Mechanism
      • 20.12.12. Distribution Channel
      • 20.12.13. End-users
    • 20.13. Rest of Europe Protein Degraders (PROTACs & Molecular Glues) Market
      • 20.13.1. Country Segmental Analysis
      • 20.13.2. Technology Type
      • 20.13.3. Target Protein Class
      • 20.13.4. E3 Ligase Type
      • 20.13.5. Molecule Type
      • 20.13.6. Route of Administration
      • 20.13.7. Therapeutic Application
      • 20.13.8. Drug Development Stage
      • 20.13.9. Linker Chemistry
      • 20.13.10. Molecular Weight
      • 20.13.11. Degradation Mechanism
      • 20.13.12. Distribution Channel
      • 20.13.13. End-users
  • 21. Asia Pacific Protein Degraders (PROTACs & Molecular Glues) Market Analysis
    • 21.1. Key Segment Analysis
    • 21.2. Regional Snapshot
    • 21.3. East Asia Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 21.3.1. Technology Type
      • 21.3.2. Target Protein Class
      • 21.3.3. E3 Ligase Type
      • 21.3.4. Molecule Type
      • 21.3.5. Route of Administration
      • 21.3.6. Therapeutic Application
      • 21.3.7. Drug Development Stage
      • 21.3.8. Linker Chemistry
      • 21.3.9. Molecular Weight
      • 21.3.10. Degradation Mechanism
      • 21.3.11. Distribution Channel
      • 21.3.12. End-users
      • 21.3.13. Country
        • 21.3.13.1. China
        • 21.3.13.2. India
        • 21.3.13.3. Japan
        • 21.3.13.4. South Korea
        • 21.3.13.5. Australia and New Zealand
        • 21.3.13.6. Indonesia
        • 21.3.13.7. Malaysia
        • 21.3.13.8. Thailand
        • 21.3.13.9. Vietnam
        • 21.3.13.10. Rest of Asia Pacific
    • 21.4. China Protein Degraders (PROTACs & Molecular Glues) Market
      • 21.4.1. Country Segmental Analysis
      • 21.4.2. Technology Type
      • 21.4.3. Target Protein Class
      • 21.4.4. E3 Ligase Type
      • 21.4.5. Molecule Type
      • 21.4.6. Route of Administration
      • 21.4.7. Therapeutic Application
      • 21.4.8. Drug Development Stage
      • 21.4.9. Linker Chemistry
      • 21.4.10. Molecular Weight
      • 21.4.11. Degradation Mechanism
      • 21.4.12. Distribution Channel
      • 21.4.13. End-users
    • 21.5. India Protein Degraders (PROTACs & Molecular Glues) Market
      • 21.5.1. Country Segmental Analysis
      • 21.5.2. Technology Type
      • 21.5.3. Target Protein Class
      • 21.5.4. E3 Ligase Type
      • 21.5.5. Molecule Type
      • 21.5.6. Route of Administration
      • 21.5.7. Therapeutic Application
      • 21.5.8. Drug Development Stage
      • 21.5.9. Linker Chemistry
      • 21.5.10. Molecular Weight
      • 21.5.11. Degradation Mechanism
      • 21.5.12. Distribution Channel
      • 21.5.13. End-users
    • 21.6. Japan Protein Degraders (PROTACs & Molecular Glues) Market
      • 21.6.1. Country Segmental Analysis
      • 21.6.2. Technology Type
      • 21.6.3. Target Protein Class
      • 21.6.4. E3 Ligase Type
      • 21.6.5. Molecule Type
      • 21.6.6. Route of Administration
      • 21.6.7. Therapeutic Application
      • 21.6.8. Drug Development Stage
      • 21.6.9. Linker Chemistry
      • 21.6.10. Molecular Weight
      • 21.6.11. Degradation Mechanism
      • 21.6.12. Distribution Channel
      • 21.6.13. End-users
    • 21.7. South Korea Protein Degraders (PROTACs & Molecular Glues) Market
      • 21.7.1. Country Segmental Analysis
      • 21.7.2. Technology Type
      • 21.7.3. Target Protein Class
      • 21.7.4. E3 Ligase Type
      • 21.7.5. Molecule Type
      • 21.7.6. Route of Administration
      • 21.7.7. Therapeutic Application
      • 21.7.8. Drug Development Stage
      • 21.7.9. Linker Chemistry
      • 21.7.10. Molecular Weight
      • 21.7.11. Degradation Mechanism
      • 21.7.12. Distribution Channel
      • 21.7.13. End-users
    • 21.8. Australia and New Zealand Protein Degraders (PROTACs & Molecular Glues) Market
      • 21.8.1. Country Segmental Analysis
      • 21.8.2. Technology Type
      • 21.8.3. Target Protein Class
      • 21.8.4. E3 Ligase Type
      • 21.8.5. Molecule Type
      • 21.8.6. Route of Administration
      • 21.8.7. Therapeutic Application
      • 21.8.8. Drug Development Stage
      • 21.8.9. Linker Chemistry
      • 21.8.10. Molecular Weight
      • 21.8.11. Degradation Mechanism
      • 21.8.12. Distribution Channel
      • 21.8.13. End-users
    • 21.9. Indonesia Protein Degraders (PROTACs & Molecular Glues) Market
      • 21.9.1. Country Segmental Analysis
      • 21.9.2. Technology Type
      • 21.9.3. Target Protein Class
      • 21.9.4. E3 Ligase Type
      • 21.9.5. Molecule Type
      • 21.9.6. Route of Administration
      • 21.9.7. Therapeutic Application
      • 21.9.8. Drug Development Stage
      • 21.9.9. Linker Chemistry
      • 21.9.10. Molecular Weight
      • 21.9.11. Degradation Mechanism
      • 21.9.12. Distribution Channel
      • 21.9.13. End-users
    • 21.10. Malaysia Protein Degraders (PROTACs & Molecular Glues) Market
      • 21.10.1. Country Segmental Analysis
      • 21.10.2. Technology Type
      • 21.10.3. Target Protein Class
      • 21.10.4. E3 Ligase Type
      • 21.10.5. Molecule Type
      • 21.10.6. Route of Administration
      • 21.10.7. Therapeutic Application
      • 21.10.8. Drug Development Stage
      • 21.10.9. Linker Chemistry
      • 21.10.10. Molecular Weight
      • 21.10.11. Degradation Mechanism
      • 21.10.12. Distribution Channel
      • 21.10.13. End-users
    • 21.11. Thailand Protein Degraders (PROTACs & Molecular Glues) Market
      • 21.11.1. Country Segmental Analysis
      • 21.11.2. Technology Type
      • 21.11.3. Target Protein Class
      • 21.11.4. E3 Ligase Type
      • 21.11.5. Molecule Type
      • 21.11.6. Route of Administration
      • 21.11.7. Therapeutic Application
      • 21.11.8. Drug Development Stage
      • 21.11.9. Linker Chemistry
      • 21.11.10. Molecular Weight
      • 21.11.11. Degradation Mechanism
      • 21.11.12. Distribution Channel
      • 21.11.13. End-users
    • 21.12. Vietnam Protein Degraders (PROTACs & Molecular Glues) Market
      • 21.12.1. Country Segmental Analysis
      • 21.12.2. Technology Type
      • 21.12.3. Target Protein Class
      • 21.12.4. E3 Ligase Type
      • 21.12.5. Molecule Type
      • 21.12.6. Route of Administration
      • 21.12.7. Therapeutic Application
      • 21.12.8. Drug Development Stage
      • 21.12.9. Linker Chemistry
      • 21.12.10. Molecular Weight
      • 21.12.11. Degradation Mechanism
      • 21.12.12. Distribution Channel
      • 21.12.13. End-users
    • 21.13. Rest of Asia Pacific Protein Degraders (PROTACs & Molecular Glues) Market
      • 21.13.1. Country Segmental Analysis
      • 21.13.2. Technology Type
      • 21.13.3. Target Protein Class
      • 21.13.4. E3 Ligase Type
      • 21.13.5. Molecule Type
      • 21.13.6. Route of Administration
      • 21.13.7. Therapeutic Application
      • 21.13.8. Drug Development Stage
      • 21.13.9. Linker Chemistry
      • 21.13.10. Molecular Weight
      • 21.13.11. Degradation Mechanism
      • 21.13.12. Distribution Channel
      • 21.13.13. End-users
  • 22. Middle East Protein Degraders (PROTACs & Molecular Glues) Market Analysis
    • 22.1. Key Segment Analysis
    • 22.2. Regional Snapshot
    • 22.3. Middle East Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 22.3.1. Technology Type
      • 22.3.2. Target Protein Class
      • 22.3.3. E3 Ligase Type
      • 22.3.4. Molecule Type
      • 22.3.5. Route of Administration
      • 22.3.6. Therapeutic Application
      • 22.3.7. Drug Development Stage
      • 22.3.8. Linker Chemistry
      • 22.3.9. Molecular Weight
      • 22.3.10. Degradation Mechanism
      • 22.3.11. Distribution Channel
      • 22.3.12. End-users
      • 22.3.13. Country
        • 22.3.13.1. Turkey
        • 22.3.13.2. UAE
        • 22.3.13.3. Saudi Arabia
        • 22.3.13.4. Israel
        • 22.3.13.5. Rest of Middle East
    • 22.4. Turkey Protein Degraders (PROTACs & Molecular Glues) Market
      • 22.4.1. Country Segmental Analysis
      • 22.4.2. Technology Type
      • 22.4.3. Target Protein Class
      • 22.4.4. E3 Ligase Type
      • 22.4.5. Molecule Type
      • 22.4.6. Route of Administration
      • 22.4.7. Therapeutic Application
      • 22.4.8. Drug Development Stage
      • 22.4.9. Linker Chemistry
      • 22.4.10. Molecular Weight
      • 22.4.11. Degradation Mechanism
      • 22.4.12. Distribution Channel
      • 22.4.13. End-users
    • 22.5. UAE Protein Degraders (PROTACs & Molecular Glues) Market
      • 22.5.1. Country Segmental Analysis
      • 22.5.2. Technology Type
      • 22.5.3. Target Protein Class
      • 22.5.4. E3 Ligase Type
      • 22.5.5. Molecule Type
      • 22.5.6. Route of Administration
      • 22.5.7. Therapeutic Application
      • 22.5.8. Drug Development Stage
      • 22.5.9. Linker Chemistry
      • 22.5.10. Molecular Weight
      • 22.5.11. Degradation Mechanism
      • 22.5.12. Distribution Channel
      • 22.5.13. End-users
    • 22.6. Saudi Arabia Protein Degraders (PROTACs & Molecular Glues) Market
      • 22.6.1. Country Segmental Analysis
      • 22.6.2. Technology Type
      • 22.6.3. Target Protein Class
      • 22.6.4. E3 Ligase Type
      • 22.6.5. Molecule Type
      • 22.6.6. Route of Administration
      • 22.6.7. Therapeutic Application
      • 22.6.8. Drug Development Stage
      • 22.6.9. Linker Chemistry
      • 22.6.10. Molecular Weight
      • 22.6.11. Degradation Mechanism
      • 22.6.12. Distribution Channel
      • 22.6.13. End-users
    • 22.7. Israel Protein Degraders (PROTACs & Molecular Glues) Market
      • 22.7.1. Country Segmental Analysis
      • 22.7.2. Technology Type
      • 22.7.3. Target Protein Class
      • 22.7.4. E3 Ligase Type
      • 22.7.5. Molecule Type
      • 22.7.6. Route of Administration
      • 22.7.7. Therapeutic Application
      • 22.7.8. Drug Development Stage
      • 22.7.9. Linker Chemistry
      • 22.7.10. Molecular Weight
      • 22.7.11. Degradation Mechanism
      • 22.7.12. Distribution Channel
      • 22.7.13. End-users
    • 22.8. Rest of Middle East Protein Degraders (PROTACs & Molecular Glues) Market
      • 22.8.1. Country Segmental Analysis
      • 22.8.2. Technology Type
      • 22.8.3. Target Protein Class
      • 22.8.4. E3 Ligase Type
      • 22.8.5. Molecule Type
      • 22.8.6. Route of Administration
      • 22.8.7. Therapeutic Application
      • 22.8.8. Drug Development Stage
      • 22.8.9. Linker Chemistry
      • 22.8.10. Molecular Weight
      • 22.8.11. Degradation Mechanism
      • 22.8.12. Distribution Channel
      • 22.8.13. End-users
  • 23. Africa Protein Degraders (PROTACs & Molecular Glues) Market Analysis
    • 23.1. Key Segment Analysis
    • 23.2. Regional Snapshot
    • 23.3. Africa Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 23.3.1. Technology Type
      • 23.3.2. Target Protein Class
      • 23.3.3. E3 Ligase Type
      • 23.3.4. Molecule Type
      • 23.3.5. Route of Administration
      • 23.3.6. Therapeutic Application
      • 23.3.7. Drug Development Stage
      • 23.3.8. Linker Chemistry
      • 23.3.9. Molecular Weight
      • 23.3.10. Degradation Mechanism
      • 23.3.11. Distribution Channel
      • 23.3.12. End-users
      • 23.3.13. Country
        • 23.3.13.1. South Africa
        • 23.3.13.2. Egypt
        • 23.3.13.3. Nigeria
        • 23.3.13.4. Algeria
        • 23.3.13.5. Rest of Africa
    • 23.4. South Africa Protein Degraders (PROTACs & Molecular Glues) Market
      • 23.4.1. Country Segmental Analysis
      • 23.4.2. Technology Type
      • 23.4.3. Target Protein Class
      • 23.4.4. E3 Ligase Type
      • 23.4.5. Molecule Type
      • 23.4.6. Route of Administration
      • 23.4.7. Therapeutic Application
      • 23.4.8. Drug Development Stage
      • 23.4.9. Linker Chemistry
      • 23.4.10. Molecular Weight
      • 23.4.11. Degradation Mechanism
      • 23.4.12. Distribution Channel
      • 23.4.13. End-users
    • 23.5. Egypt Protein Degraders (PROTACs & Molecular Glues) Market
      • 23.5.1. Country Segmental Analysis
      • 23.5.2. Technology Type
      • 23.5.3. Target Protein Class
      • 23.5.4. E3 Ligase Type
      • 23.5.5. Molecule Type
      • 23.5.6. Route of Administration
      • 23.5.7. Therapeutic Application
      • 23.5.8. Drug Development Stage
      • 23.5.9. Linker Chemistry
      • 23.5.10. Molecular Weight
      • 23.5.11. Degradation Mechanism
      • 23.5.12. Distribution Channel
      • 23.5.13. End-users
    • 23.6. Nigeria Protein Degraders (PROTACs & Molecular Glues) Market
      • 23.6.1. Country Segmental Analysis
      • 23.6.2. Technology Type
      • 23.6.3. Target Protein Class
      • 23.6.4. E3 Ligase Type
      • 23.6.5. Molecule Type
      • 23.6.6. Route of Administration
      • 23.6.7. Therapeutic Application
      • 23.6.8. Drug Development Stage
      • 23.6.9. Linker Chemistry
      • 23.6.10. Molecular Weight
      • 23.6.11. Degradation Mechanism
      • 23.6.12. Distribution Channel
      • 23.6.13. End-users
    • 23.7. Algeria Protein Degraders (PROTACs & Molecular Glues) Market
      • 23.7.1. Country Segmental Analysis
      • 23.7.2. Technology Type
      • 23.7.3. Target Protein Class
      • 23.7.4. E3 Ligase Type
      • 23.7.5. Molecule Type
      • 23.7.6. Route of Administration
      • 23.7.7. Therapeutic Application
      • 23.7.8. Drug Development Stage
      • 23.7.9. Linker Chemistry
      • 23.7.10. Molecular Weight
      • 23.7.11. Degradation Mechanism
      • 23.7.12. Distribution Channel
      • 23.7.13. End-users
    • 23.8. Rest of Africa Protein Degraders (PROTACs & Molecular Glues) Market
      • 23.8.1. Country Segmental Analysis
      • 23.8.2. Technology Type
      • 23.8.3. Target Protein Class
      • 23.8.4. E3 Ligase Type
      • 23.8.5. Molecule Type
      • 23.8.6. Route of Administration
      • 23.8.7. Therapeutic Application
      • 23.8.8. Drug Development Stage
      • 23.8.9. Linker Chemistry
      • 23.8.10. Molecular Weight
      • 23.8.11. Degradation Mechanism
      • 23.8.12. Distribution Channel
      • 23.8.13. End-users
  • 24. South America Protein Degraders (PROTACs & Molecular Glues) Market Analysis
    • 24.1. Key Segment Analysis
    • 24.2. Regional Snapshot
    • 24.3. Central and South Africa Protein Degraders (PROTACs & Molecular Glues) Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 24.3.1. Technology Type
      • 24.3.2. Target Protein Class
      • 24.3.3. E3 Ligase Type
      • 24.3.4. Molecule Type
      • 24.3.5. Route of Administration
      • 24.3.6. Therapeutic Application
      • 24.3.7. Drug Development Stage
      • 24.3.8. Linker Chemistry
      • 24.3.9. Molecular Weight
      • 24.3.10. Degradation Mechanism
      • 24.3.11. Distribution Channel
      • 24.3.12. End-users
      • 24.3.13. Country
        • 24.3.13.1. Brazil
        • 24.3.13.2. Argentina
        • 24.3.13.3. Rest of South America
    • 24.4. Brazil Protein Degraders (PROTACs & Molecular Glues) Market
      • 24.4.1. Country Segmental Analysis
      • 24.4.2. Technology Type
      • 24.4.3. Target Protein Class
      • 24.4.4. E3 Ligase Type
      • 24.4.5. Molecule Type
      • 24.4.6. Route of Administration
      • 24.4.7. Therapeutic Application
      • 24.4.8. Drug Development Stage
      • 24.4.9. Linker Chemistry
      • 24.4.10. Molecular Weight
      • 24.4.11. Degradation Mechanism
      • 24.4.12. Distribution Channel
      • 24.4.13. End-users
    • 24.5. Argentina Protein Degraders (PROTACs & Molecular Glues) Market
      • 24.5.1. Country Segmental Analysis
      • 24.5.2. Technology Type
      • 24.5.3. Target Protein Class
      • 24.5.4. E3 Ligase Type
      • 24.5.5. Molecule Type
      • 24.5.6. Route of Administration
      • 24.5.7. Therapeutic Application
      • 24.5.8. Drug Development Stage
      • 24.5.9. Linker Chemistry
      • 24.5.10. Molecular Weight
      • 24.5.11. Degradation Mechanism
      • 24.5.12. Distribution Channel
      • 24.5.13. End-users
    • 24.6. Rest of South America Protein Degraders (PROTACs & Molecular Glues) Market
      • 24.6.1. Country Segmental Analysis
      • 24.6.2. Technology Type
      • 24.6.3. Target Protein Class
      • 24.6.4. E3 Ligase Type
      • 24.6.5. Molecule Type
      • 24.6.6. Route of Administration
      • 24.6.7. Therapeutic Application
      • 24.6.8. Drug Development Stage
      • 24.6.9. Linker Chemistry
      • 24.6.10. Molecular Weight
      • 24.6.11. Degradation Mechanism
      • 24.6.12. Distribution Channel
      • 24.6.13. End-users
  • 25. Key Players/ Company Profile
    • 25.1. AbbVie Inc.
      • 25.1.1. Company Details/ Overview
      • 25.1.2. Company Financials
      • 25.1.3. Key Customers and Competitors
      • 25.1.4. Business/ Industry Portfolio
      • 25.1.5. Product Portfolio/ Specification Details
      • 25.1.6. Pricing Data
      • 25.1.7. Strategic Overview
      • 25.1.8. Recent Developments
    • 25.2. Amgen Inc.
    • 25.3. Arvinas, Inc.
    • 25.4. AstraZeneca plc
    • 25.5. Bayer AG
    • 25.6. Boehringer Ingelheim International GmbH
    • 25.7. Bristol Myers Squibb (Celgene)
    • 25.8. C4 Therapeutics, Inc.
    • 25.9. Captor Therapeutics S.A.
    • 25.10. Dialectic Therapeutics, Inc.
    • 25.11. Eli Lilly and Company
    • 25.12. Gilead Sciences, Inc.
    • 25.13. GSK plc (GlaxoSmithKline)
    • 25.14. Janssen Pharmaceuticals (Johnson & Johnson)
    • 25.15. Kymera Therapeutics, Inc.
    • 25.16. Merck & Co., Inc.
    • 25.17. Novartis AG
    • 25.18. Nurix Therapeutics, Inc.
    • 25.19. Pfizer Inc.
    • 25.20. Roche Holding AG (Genentech)
    • 25.21. Sanofi S.A.
    • 25.22. Takeda Pharmaceutical Company Limited
    • 25.23. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150
USD 5950
USD 7750
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation